
|Videos|August 19, 2014
Hsp90 as Potential Treatment for Lung Cancer
Author(s)Suresh S. Ramalingam, MD
Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the role of heat shock protein 90 (Hsp90) in the treatment of lung cancer.
Advertisement
Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the role of heat shock protein 90 (Hsp90) in the treatment of lung cancer.
Clinical Pearls:
- Hsp90 is a rational targeted for cancer since a number of oncoproteins depend on the associate of Hsp90 in order to become active.
- The drug ganetespib has now been combined with chemotherapy in randomized trials as a potential treatment option for lung cancer.
- GALAXY-2, a phase III trial, will randomize patients to docetaxel with or without ganetespib.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















